Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers

Next Previous
Trial Profile

A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifamycin (Primary) ; Ciprofloxacin
  • Indications Traveller's diarrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms ERASE
  • Sponsors Dr Falk Pharma

    • Most Recent Events

    • 31 Oct 2023 Results assessing to improve the prediction of prognosis and to optimize treatments, a simple risk-based clinical severity classification has been developed from Pooled data from NCT01142089 and NCT01208922, published in the Journal of Travel Medicine.
    • 05 Dec 2022 According to RedHill Biopharma media release, company announced that the U.S. Food and Drug Administration's (FDA) Exclusivity Board has granted Aemcolo five years exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, in addition to the five years' data exclusivity granted as a new chemical entity (NCE) for the treatment of travelers diarrhea (TD) caused by non-invasive strains of Escherichia coli (E. coli) in adults.
    • 23 May 2021 Results of a pooled analysis of data from two phase III studies (NCT01142089 and NCT01208922) reassessing the efficacy of Rifamycin SV presented at the Digestive Disease Week 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top